Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a less extensive stomach surgery preserve appetite better?

NCT ID NCT06243757

Symptom relief Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study compares two minimally invasive surgeries for cancer at the top of the stomach or where the stomach meets the esophagus: removing only the upper part (proximal gastrectomy) versus removing the entire stomach (total gastrectomy). The goal is to see which approach leads to better appetite and fewer digestive symptoms in the year after surgery. Participants will complete symptom questionnaires before and at several points after their operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
minimally invasive proximal gastrectomy (MIPG) versus minimally invasive total gastrectomy (MITG)
What this could lead to
If one surgery leads to better appetite and fewer symptoms, it could become the preferred option for patients with upper stomach cancer.
What could go wrong
This is a very small pilot study with only 4 participants, so results may not apply broadly. Surgery type is chosen as part of routine care, not randomly assigned.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

4 people

The number who actually took part.

Started

Jan 2024

Expected to finish

Jan 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The initial contact with the potential participants will be conducted either by the treatment team, investigator or the research staff working in consultation with the treatment team. Participants will be screened in gastric and mixed tumor surgery clinics on the 5th floor of the MSKCC 53rd Street outpatient clinic building. The investigator/research staff will review portions of the medical record to determine if they are eligible. Participants who are eligible will be approached by study personnel in clinic. The study will be explained to participants by the study personnel and interested participants will be given the consent form to review.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to speak and read English, Spanish, Japanese or Korean * Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention * Age ≥ 18 Exclusion Criteria: * Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract * Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent * Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion * Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Gastroesophageal cancer Gastroesophageal junction adenocarcinoma

Contacts and locations

Locations

  • MD Anderson Cancer Center (Data Analysis Only)

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (All protocol activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (All Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.